On or around 07/29/2019 (Other)
Filing Date: July 01, 2019
According to the Complaint, Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development, and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.
This action stems from a proposed transaction announced on June 17, 2019, pursuant to which Array BioPharma Inc. will be acquired by Pfizer Inc.
On June 14, 2019, Array’s Board of Directors caused the Company to enter into an agreement and plan of merger with Pfizer.
On June 28, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction.
The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.
This case was voluntarily dismissed on July 26, 2019.
Company & Securities Information
Defendant: Array BioPharma Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ARRY
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Michael Kent, et al. v. Array BioPharma Inc., et al.